Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis
Thrombolysis in Myocardial Infarction Study Group · Harvard University · +6 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
611
total citations
- FWCI
- 53.49
- Percentile
- 100%
- References
- 31
Citations per year
Authors
9- JLJessica L. MegaCorresponding
Thrombolysis in Myocardial Infarction Study Group, Harvard University, Brigham and Women's Hospital
- SCSandra Close
Eli Lilly (United States), Indiana University – Purdue University Indianapolis
- SDStephen D. Wiviott
Harvard University, Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital
- LSLei Shen
Eli Lilly (United States)
- JRJoseph R. Walker
Daiichi Sankyo (United States)
Topics & keywords
Topics
Keywords
- Prasugrel
- Clopidogrel
- CYP2C19
- Medicine
- Internal medicine
- Myocardial infarction
- Pharmacogenetics
- Genotype
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.